Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma

Basit Öğe Kaydı
dc.authoridDogu, Mehmet Hilmi/0000-0001-7237-2637
dc.authoridKaynar, Leylagul/0000-0002-2035-9462
dc.authoridEREN, Rafet/0000-0003-0973-6279
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridilkkilic, kadir/0000-0003-1136-0514
dc.authoridilkkilic, kadir/0000-0003-1136-0514
dc.authoridAltuntas, Fevzi/0000-0001-6872-3780
dc.authorwosidDogu, Mehmet Hilmi/W-2255-2017
dc.authorwosidKaynar, Leylagul/F-6991-2013
dc.authorwosidEREN, Rafet/G-1879-2019
dc.authorwosidKAYA, Ali/KFA-9478-2024
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidilkkilic, kadir/CAI-2651-2022
dc.authorwosidilkkilic, kadir/CAF-7643-2022
dc.contributor.authorDogu, Mehmet Hilmi
dc.contributor.authorCagirgan, Seckin
dc.contributor.authorOcakci, Serkan
dc.contributor.authorKaya, Ali Hakan
dc.contributor.authorIlkkilic, Kadir
dc.contributor.authorSanli, Neslihan Mandaci
dc.contributor.authorKahraman, Selda
dc.date.accessioned2024-08-04T20:44:06Z
dc.date.available2024-08-04T20:44:06Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAs known, the world population is aging and as the life span increases the number of advanced-age lymphomas also shows an upward trend. Autologous hematopoietic stem cell transplantation (HSCT) is the standard treatment modality in chemotherapy-sensitive relapsed or refractory aggressive lymphomas. Increased morbidity and mortality related to both the transplant itself and comorbid diseases can be observed in elderly lymphoma patients. Patients who are 65 years or older and underwent autologous HSCT with B-cell non-Hodgkin lymphoma were retrospectively included in our study. In terms of survival analysis, median follow-up was 34.5 months (8-159) while the overall survival (OS) was 58%. In the univariate analysis of prognostic data in OS, patients who were referred to transplantation with complete response had a statistically significant survival advantage (p=0.043). In terms of the effect of pre-transplant conditioning regimens on survival, BEAM regimen yielded better results, though not statistically significant. Age, number of chemotherapy cycles received before mobilization and radiation therapy had no significant effect on the CD34 (+) cell count in the final product (p = 0.492, 0.746 and 0.078 respectively). In conclusion, autologous HSCT is a practicable treatment modality that provides survival advantage in suitable advanced-age patients with a diagnosis of B-cell non-Hodgkin lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.transci.2017.11.012
dc.identifier.endpage818en_US
dc.identifier.issn1473-0502
dc.identifier.issue6en_US
dc.identifier.pmid29153347en_US
dc.identifier.scopus2-s2.0-85034451361en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage814en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2017.11.012
dc.identifier.urihttps://hdl.handle.net/11616/98033
dc.identifier.volume56en_US
dc.identifier.wosWOS:000423246100011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectB-cell non-Hodgkin lymphomaen_US
dc.subjectAutologous hematopoietic stem cell transplantationen_US
dc.subjectElderly patientsen_US
dc.subjectMobilizationen_US
dc.titleAutologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu